A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

Last updated: June 6, 2025
Sponsor: M.D. Anderson Cancer Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Neoplasm Metastasis

Metastatic Cancer

Treatment

Metastatic Cancer

Clinical Study ID

NCT06693687
2024-0229
NCI-2024-09566
  • Ages > 18
  • All Genders

Study Summary

To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare.

Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 years of age or older

  • Confirmed diagnosis of cancer

  • Part 1 (Run-in Phase): Only patients with prostate, kidney, and/or bladdercancer will be enrolled with either localized or metastatic disease.

  • Part 2 (Expansion Phase): Metastatic patients will be enrolled. Note, evaluablemetastatic patients from Ppart 1 will be counted in Cohort A as described insection 8.4.

  • Planned to receive systemic anti-cancer therapy

  • Ability to understand and the willingness to sign a written informed consentdocument

  • Ability to speak, read, and understand one of the following languages: English,Spanish, Mandarin and Cantonese Chinese

  • Ownership of a smartphone and willingness to use it as outlined by the protocol anddescribed in the ICF

Exclusion

Exclusion Criteria:

  • Have any medical, psychological, or social condition that, in the opinion of theinvestigator would preclude participation in this study (pregnancy is notexclusionary and pregnant women will be permitted to enroll in the study).

Study Design

Total Participants: 425
Treatment Group(s): 1
Primary Treatment: Metastatic Cancer
Phase:
Study Start date:
December 18, 2024
Estimated Completion Date:
November 01, 2027

Study Description

Primary Objective • To determine the rate of therapy discontinuation due to toxicity among patients using ApricityCare.

Secondary Objectives

• To evaluate time the ease and experience of patient use of ApricityCare (i.e., patient engagement) in reporting symptoms during their systemic cancer treatments. Furthermore, the frequency of patient symptom reporting via check-in to ApricityCare will be evaluated, as will the time taken to respond and engage patients after they report toxicity or other adverse events via ApricityCare.

Connect with a study center

  • MD Anderson Cancer Center

    Houston, Texas 77030
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.